Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin (DC-SIGN)
- Target
- DC-SIGN
- Molecular classification
- C-type lectin receptor, Type II transmembrane protein
01
Overview
Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin (DC-SIGN/CD209) is a C-type lectin receptor primarily expressed on immature dendritic cells and certain macrophage populations. It functions as a pathogen recognition receptor, binding high-mannose carbohydrates on pathogens like HIV and dengue virus, facilitating their entry into cells. It also acts as a cell adhesion molecule, interacting with ICAM-3 on T lymphocytes to initiate T-cell activation. DC-SIGN ligation can lead to increased anti-inflammatory cytokine release, influencing the tumor microenvironment and potentially promoting tumor progression. Due to its role in both pathogen recognition and immune modulation, it is a target for research in infectious diseases, cancer immunology, and vaccine development.
- Other names
- CD209
02
Mechanism of action
Modulation of DC-SIGN-mediated immune responses
03
Biological functions
Pathogen recognitionCell adhesionImmune modulationAntigen presentation
04
Disease associations
InfectionCancerImmune disorders
05
Safety considerations
Potential for off-target effects due to glycan bindingModulation of immune responses could lead to unintended consequences
Beyond the preview
Go deeper on Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin (DC-SIGN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin (DC-SIGN).